One-time therapy may be ‘transformative option' for treating deadly skin cancer
Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, a trial has found.
Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which involves isolating T cells – a type of white blood cell – from tumours and growing them in a lab before infusing them back into the patient where they can recognise and fight cancer.
It could become a 'transformative option' for patients with this type of skin cancer, experts said.
Cancer Research UK estimates that there are about 20,800 new cases of melanoma diagnosed in the UK every year.
Advanced melanoma, also known as stage four melanoma, means the disease has spread to other parts of the body.
The C-144-01 trial involved 153 patients from Europe and the US, and was led by The Royal Marsden NHS Foundation Trust.
At a five-year follow up, 19.7% of patients were still alive with no new or delayed side effects.
The trial also found that tumours shrank in almost four out of five (79.3%) patients, while one in 20 (5.9%) showed no evidence of cancer.
Dr Andrew Furness, a consultant medical oncologist who led the trial at The Royal Marsden NHS Foundation Trust, said: 'While current forms of immunotherapy have revolutionised the treatment of cancer in recent years, overall these benefit a minority rather than majority of treated patients.
'Results from this trial have shown that TIL therapy may change the outlook for people with advanced melanoma.'
Lifileucel is not yet approved for use in the UK, but was given the green light by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma in February 2024.
Trials are also looking at using the TIL therapy in combination with pembrolizumab, sold under the brand name Keytruda, for people with advanced melanoma.
Keytruda works by targeting and blocking a protein known as PD-L1, which is found on T cells, to help the immune system fight cancer more effectively.
Dr Furness added: 'We're continuing our research into the use of TIL therapy, as well as other forms of cellular therapy, across a broader spectrum of cancers including advanced lung, liver, ovary, skin and testicular subtypes as well as soft tissue sarcoma.'
Study co-author James Larkin, consultant medical oncologist at The Royal Marsden and professor of precision cancer therapeutics at The Institute of Cancer Research, London, said: 'These significant results offer a compelling case for TIL therapy as a transformative option in melanoma care.
'The study demonstrates that for patients with few options left, a single infusion of lifileucel can provide a deep and lasting response and even complete remission in some cases. This marks a major advance in how we think about treating solid tumours.'
Zoe Phillips, 46, from Dorset took part in the TIL therapy trial at The Royal Marsden.
She was diagnosed with stage four melanoma in 2023 after previously being treated for skin cancer two years earlier.
'Six weeks after my first TIL therapy treatment, my scans showed that the tumours had completely disappeared,' Ms Phillips said.
'Before coming to The Royal Marsden I was told that I would probably die, so hearing that my treatment had been successful was amazing, I was over the moon.
'I come back to the hospital regularly for pembrolizumab immunotherapy treatment and currently still have no evidence of cancer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wales Online
20 hours ago
- Wales Online
'New way to find traces of cancer has extended my life'
'New way to find traces of cancer has extended my life' An MRI scan has been developed that can find minuscule amounts of the disease when traditional tests can't Air Vice-Marshal Fin Monahan (Image: Royal Marsden Hospital/PA Wire ) Scientists have found a new way to find tiny traces of cancer that could help 'revolutionise' care for patients with a certain form of blood cancer. Giving patients a whole-body MRI scan can detect minuscule amounts of myeloma, also known as minimal residue disease, even when traditional tests showed no signs of cancer, researchers found. Usual tests include blood tests and bone marrow biopsies, CT scans and X-rays. Experts said that this scanning technique can provide an important insight into how well patients are responding to treatment and whether they might relapse. Myeloma is a type of blood cancer that develops from plasma cells in the bone marrow. The condition is sometimes called multiple myeloma because it affects more than one part of the body. The disease is not considered curable but treatment can control it. Researchers at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, tracked 70 myeloma patients who were having a stem cell transplant. They were all given a whole-body MRI before and after the treatment. Writing in the Blood Cancer Journal, experts said that one in three patients had signs of residual disease on whole-body MRI after treatment – which can be given to patients without the use of radiation. Overall survival was also significantly shorter in those with positive MRI findings. The Royal Marsden has already adopted the the whole-body imagine technique and it could help shape cancer care for patients around the country in the future. One patient under the treatment of the hospital described how the scanning technique 'extended his life' and enabled him to 'continue serving' the country. Air Vice-Marshal Fin Monahan, chief fire officer for South Wales Fire and Rescue Service, was diagnosed with myeloma in 2009 while serving in the RAF. He has since relapsed twice, but thanks to whole-body MRI scans, his cancer was detected much earlier than would have been possible with a traditional CT scan. The father of three, 57, said: 'With the constant threat of relapse, myeloma patients are in a long-term mental battle with this insidious disease. However, being part of the whole-body MRI scan study at the Royal Marsden allowed my cancer to be closely watched and resulted in me being treated sooner than I would have been under normal protocols. 'This not only extended my life but after diagnosis, I returned to flying jets and to active operational duties. I would eventually not be allowed to fly on medical grounds due to myeloma but paved the way to establishing the first training programme of Ukrainian forces in 2015 and I was called upon to run Nato air operations after the invasion of Ukraine. This cutting-edge treatment not only extended my life but allowed me to continue serving my country.' Study chief investigator, Professor Christina Messiou, consultant radiologist at The Royal Marsden NHS Foundation Trust, and professor in imaging for personalised oncology at The Institute of Cancer Research, said: 'This study shows that whole-body MRI gives us valuable information about how well the myeloma has responded to treatment that other tests may miss. It's exciting that we now have a standardised, non-invasive imaging method that can be used across cancer centres. 'Whole-body MRI doesn't involve radiation or intravenous injections, which is important for patients who may require lifelong monitoring. This is an important step towards smarter and kinder precision diagnostics for patients with cancer.' Professor Martin Kaiser, consultant haematologist at The Royal Marsden NHS Foundation Trust and professor in molecular haematology at The Institute of Cancer Research, London, added: 'Access to this gold-standard precision imaging with whole-body MRI has revolutionised care for myeloma patients. Article continues below 'As the treatment options for myeloma increase and factors such as disease distribution across the body are increasingly understood as important to treatment response, the relevance of the whole-body MRI for personalising treatment will only increase over time.' Around 6,200 people are diagnosed with the condition each year in the UK and charity Myeloma UK estimates that there are around 33,000 people living with myeloma in the UK.
Leader Live
a day ago
- Leader Live
‘Exciting' new diagnostic method can detect tiny traces of cancer
Giving patients a whole-body MRI scan can detect minuscule amounts of myeloma, also known as minimal residue disease, even when traditional tests showed no signs of cancer, researchers found. Usual tests include blood tests and bone marrow biopsies, CT scans and X rays. Experts said that this scanning technique can provide an important insight into how well patients are responding to treatment and whether they might relapse. Myeloma is a type of blood cancer that develops from plasma cells in the bone marrow. The condition is sometimes called multiple myeloma because it affects more than one part of the body. The disease is not considered curable but treatment can control it. Researchers at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, tracked 70 myeloma patients who were having a stem cell transplant. 1/2 Many people living with myeloma experience symptoms for months or even years before receiving a diagnosis. By sharing this post, you can help raise awareness and make sure more people recognise the warning signs sooner ⚠️ #MyelomaAwarenessWeek #MyelomaWarningSigns — Myeloma UK (@MyelomaUK) June 16, 2025 They were all given a whole-body MRI before and after the treatment. Writing in the Blood Cancer Journal, experts said that one in three patients had signs of residual disease on whole-body MRI after treatment – which can be given to patients without the use of radiation. Overall survival was also significantly shorter in those with positive MRI findings. The Royal Marsden has already adopted the the whole-body imagine technique and it could help shape cancer care for patients around the country in the future. One patient under the treatment of the hospital described how the scanning technique 'extended his life' and enabled him to 'continue serving' the country. Air Vice-Marshal Fin Monahan, chief fire officer for South Wales Fire and Rescue Service, was diagnosed with myeloma in 2009 while serving in the RAF. He has since relapsed twice, but thanks to whole-body MRI scans, his cancer was detected much earlier than would have been possible with a traditional CT scan. The father of three, 57, said: 'With the constant threat of relapse, myeloma patients are in a long-term mental battle with this insidious disease. 'However, being part of the whole-body MRI scan study at the Royal Marsden allowed my cancer to be closely watched and resulted in me being treated sooner than I would have been under normal protocols. 'This not only extended my life but after diagnosis, I returned to flying jets and to active operational duties. 'I would eventually not be allowed to fly on medical grounds due to myeloma but paved the way to establishing the first training programme of Ukrainian forces in 2015 and I was called upon to run Nato air operations after the invasion of Ukraine. 'This cutting-edge treatment not only extended my life but allowed me to continue serving my country.' Study chief investigator, Professor Christina Messiou, consultant radiologist at The Royal Marsden NHS Foundation Trust, and professor in imaging for personalised oncology at The Institute of Cancer Research, said: 'This study shows that whole-body MRI gives us valuable information about how well the myeloma has responded to treatment that other tests may miss. 'It's exciting that we now have a standardised, non-invasive imaging method that can be used across cancer centres. 'Whole-body MRI doesn't involve radiation or intravenous injections, which is important for patients who may require lifelong monitoring. 'This is an important step towards smarter and kinder precision diagnostics for patients with cancer' Professor Martin Kaiser, consultant haematologist at The Royal Marsden NHS Foundation Trust and professor in molecular haematology at The Institute of Cancer Research, London, added: 'Access to this gold-standard precision imaging with whole-body MRI has revolutionised care for myeloma patients. 'As the treatment options for myeloma increase and factors such as disease distribution across the body are increasingly understood as important to treatment response, the relevance of the whole-body MRI for personalising treatment will only increase over time.' Around 6,200 people are diagnosed with the condition each year in the UK and charity Myeloma UK estimates that there are around 33,000 people living with myeloma in the UK.
Powys County Times
a day ago
- Powys County Times
‘Exciting' new diagnostic method can detect tiny traces of cancer
Scientists have found a new way to find tiny traces of cancer which could help 'revolutionise' care for patients with a certain form of blood cancer. Giving patients a whole-body MRI scan can detect minuscule amounts of myeloma, also known as minimal residue disease, even when traditional tests showed no signs of cancer, researchers found. Usual tests include blood tests and bone marrow biopsies, CT scans and X rays. Experts said that this scanning technique can provide an important insight into how well patients are responding to treatment and whether they might relapse. Myeloma is a type of blood cancer that develops from plasma cells in the bone marrow. The condition is sometimes called multiple myeloma because it affects more than one part of the body. The disease is not considered curable but treatment can control it. Researchers at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, tracked 70 myeloma patients who were having a stem cell transplant. 1/2 Many people living with myeloma experience symptoms for months or even years before receiving a diagnosis. By sharing this post, you can help raise awareness and make sure more people recognise the warning signs sooner ⚠️ #MyelomaAwarenessWeek #MyelomaWarningSigns — Myeloma UK (@MyelomaUK) June 16, 2025 They were all given a whole-body MRI before and after the treatment. Writing in the Blood Cancer Journal, experts said that one in three patients had signs of residual disease on whole-body MRI after treatment – which can be given to patients without the use of radiation. Overall survival was also significantly shorter in those with positive MRI findings. The Royal Marsden has already adopted the the whole-body imagine technique and it could help shape cancer care for patients around the country in the future. One patient under the treatment of the hospital described how the scanning technique 'extended his life' and enabled him to 'continue serving' the country. Air Vice-Marshal Fin Monahan, chief fire officer for South Wales Fire and Rescue Service, was diagnosed with myeloma in 2009 while serving in the RAF. He has since relapsed twice, but thanks to whole-body MRI scans, his cancer was detected much earlier than would have been possible with a traditional CT scan. The father of three, 57, said: 'With the constant threat of relapse, myeloma patients are in a long-term mental battle with this insidious disease. 'However, being part of the whole-body MRI scan study at the Royal Marsden allowed my cancer to be closely watched and resulted in me being treated sooner than I would have been under normal protocols. 'This not only extended my life but after diagnosis, I returned to flying jets and to active operational duties. 'I would eventually not be allowed to fly on medical grounds due to myeloma but paved the way to establishing the first training programme of Ukrainian forces in 2015 and I was called upon to run Nato air operations after the invasion of Ukraine. 'This cutting-edge treatment not only extended my life but allowed me to continue serving my country.' Study chief investigator, Professor Christina Messiou, consultant radiologist at The Royal Marsden NHS Foundation Trust, and professor in imaging for personalised oncology at The Institute of Cancer Research, said: 'This study shows that whole-body MRI gives us valuable information about how well the myeloma has responded to treatment that other tests may miss. 'It's exciting that we now have a standardised, non-invasive imaging method that can be used across cancer centres. 'Whole-body MRI doesn't involve radiation or intravenous injections, which is important for patients who may require lifelong monitoring. 'This is an important step towards smarter and kinder precision diagnostics for patients with cancer' Professor Martin Kaiser, consultant haematologist at The Royal Marsden NHS Foundation Trust and professor in molecular haematology at The Institute of Cancer Research, London, added: 'Access to this gold-standard precision imaging with whole-body MRI has revolutionised care for myeloma patients. 'As the treatment options for myeloma increase and factors such as disease distribution across the body are increasingly understood as important to treatment response, the relevance of the whole-body MRI for personalising treatment will only increase over time.' Around 6,200 people are diagnosed with the condition each year in the UK and charity Myeloma UK estimates that there are around 33,000 people living with myeloma in the UK.
